Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

A new brain-imaging study has revealed how ketamine produces its fast antidepressant effects in people with treatment-resistant depression. Researchers tracked changes in a critical brain receptor ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients ...

Researchers used a novel PET tracer to visualize how ketamine alters AMPA receptor distribution in the brains of patients ...

This framework was applied to neural recordings from animals receiving one of the three anesthetics—propofol, ketamine, and dexmedetomidine.

Major depressive disorder (MDD) is a major global health problem and one of the leading causes of disability. About 30% of people diagnosed with ...

When patients undergo general anesthesia, doctors can choose among several drugs. Although each of these drugs acts on neurons in different ways, they all lead to the same result: a disruption of the ...

Positron emission tomography (PET) images using the novel tracer [¹¹C]K-2 visualize cell-surface α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) density in the living human brain ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives discussed upcoming clinical readouts and pipeline priorities during the ...